|
GB0013810D0
(en)
*
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
WO2003033677A2
(en)
*
|
2001-10-19 |
2003-04-24 |
Zymogenetics, Inc. |
Dimerized growth factor and materials and methods for producing it
|
|
GB0303337D0
(en)
|
2003-02-13 |
2003-03-19 |
Celltech R&D Ltd |
Biological products
|
|
WO2005000899A2
(en)
*
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
US20070269428A1
(en)
|
2003-11-21 |
2007-11-22 |
Celltech R&D Limited |
Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
|
|
WO2005087810A2
(en)
*
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
CA2606102C
(en)
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
AU2006290567A1
(en)
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A |
Comb polymers
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
EP3524626A1
(en)
|
2007-03-22 |
2019-08-14 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
|
CN104004088B
(zh)
|
2007-09-26 |
2017-11-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
|
ES2667258T3
(es)
|
2009-09-10 |
2018-05-10 |
Ucb Biopharma Sprl |
Anticuerpos multivalentes
|
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
WO2011117653A1
(en)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Disulfide stabilized dvd-lg molecules
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
EP2565667A1
(en)
|
2011-08-31 |
2013-03-06 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Direction of arrival estimation using watermarked audio signals and microphone arrays
|
|
EP2753697A1
(en)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
|
MX351502B
(es)
|
2011-11-11 |
2017-10-18 |
Ucb Pharma Sa |
Anticuerpos de union de albumina y fragmentos de union de los mismos.
|
|
CN104684928A
(zh)
|
2012-08-02 |
2015-06-03 |
Jn生物科学有限责任公司 |
通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
|
|
JP6851200B2
(ja)
|
2014-03-05 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
多量体Ｆｃタンパク質
|
|
BR112017025263A2
(pt)
|
2015-05-27 |
2018-08-07 |
Ucb Biopharma Sprl |
método para o tratamento de doença neurológica
|
|
AU2016304764C1
(en)
*
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
AU2018382586A1
(en)
|
2017-12-14 |
2020-07-02 |
CSL Behring Lengnau AG |
Recombinant igG Fc multimers for the treatment of neuromyelitis optica
|
|
GB201804243D0
(en)
*
|
2018-03-16 |
2018-05-02 |
Liverpool School Tropical Medicine |
Hinge sequences
|
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
WO2020236795A2
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
|
MX2021014164A
(es)
|
2019-05-21 |
2022-01-04 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
|
AU2020327000A1
(en)
|
2019-08-08 |
2022-03-31 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
JP2022547692A
(ja)
|
2019-09-13 |
2022-11-15 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
|
|
MX2022005330A
(es)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharma |
Moleculas de union multiespecificas con scfv en el extremo nterminal.
|
|
TW202136317A
(zh)
|
2019-12-20 |
2021-10-01 |
美商再生元醫藥公司 |
新穎之ｉｌ２促效劑及其使用方法（二）
|
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
BR112022022899A2
(pt)
|
2020-05-12 |
2022-12-20 |
Regeneron Pharma |
Agonistas de il10 e métodos de uso dos mesmos
|
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20220372168A1
(en)
|
2021-05-04 |
2022-11-24 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
IL310221A
(en)
|
2021-07-19 |
2024-03-01 |
Regeneron Pharma |
IL12 receptor agonists and methods of using them
|
|
TW202322846A
(zh)
|
2021-08-16 |
2023-06-16 |
美商再生元醫藥公司 |
新穎的il27受體促效劑及其使用方法
|
|
US20230279153A1
(en)
|
2021-11-11 |
2023-09-07 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
